Halozyme Therapeutics (HALO) USPTO patents

Utility

Combination Therapy with a Hyaluronan-degrading Enzyme and an Immune Checkpoint Inhibitor

24 Nov 22

Provided are methods of treatment of cancers with combinations of and compositions containing a soluble hyaluronidase, such as a polymer-modified soluble hyaluronidase, and an immune checkpoint inhibitor for treating cancers, including solid and non-solid tumors.

Sanna ROSENGREN, H. Michael SHEPARD, Curtis B. THOMPSON

Filed: 27 Jun 22

Utility

Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

16 Aug 22

Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors.

Sanna Rosengren, H. Michael Shepard, Curtis B. Thompson

Filed: 27 Feb 17

Utility

Methods of Treating Tumors

28 Jul 22

The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Masano Huang, Thomas Arthur Haby, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO

Filed: 27 Dec 21

Utility

Antibody Compositions and Methods of Use Thereof

28 Jul 22

The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants.

Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO

Filed: 27 Dec 21

Utility

PH20 Polypeptide Variants, Formulations and Uses Thereof

16 Sep 21

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.

Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor

Filed: 21 May 21

Utility

PH20 Polypeptide Variants, Formulations and Uses Thereof

9 Sep 21

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.

Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor

Filed: 21 May 21

Utility

PH20 polypeptide variants, formulations and uses thereof

20 Jul 21

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.

Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor

Filed: 25 Jun 20

Utility

PH20 polypeptide variants, formulations and uses thereof

22 Jun 21

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.

Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor

Filed: 19 Mar 20

Utility

SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF

28 Jan 21

Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration for in vitro fertilization, as well as administration of molecules, or to alleviate glycosaminoglycan associated pathologies.

Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost

Filed: 2 Oct 20

Utility

Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

26 Jan 21

Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies.

Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost

Filed: 2 Apr 19

Utility

PH20 polypeptide variants, formulations and uses thereof

14 Dec 20

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.

Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor

Filed: 1 Aug 16

Utility

Modified Hyaluronidases and Uses In Treating Hyaluronan-associated Diseases and Conditions

25 Nov 20

Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders.

Gregory I. Frost, Ping Jiang, Curtis B. Thompson

Filed: 15 Jul 20

Utility

PH20 Polypeptide Variants, Formulations and Uses Thereof

7 Oct 20

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.

GE WEI, H. MICHAEL SHEPARD, QIPING ZHAO, ROBERT JAMES CONNOR

Filed: 24 Jun 20

Utility

PH20 Polypeptide Variants, Formulations and Uses Thereof

12 Aug 20

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.

Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor

Filed: 18 Mar 20

Utility

Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

16 Mar 20

The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies.

Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost

Filed: 22 Feb 18

Utility

Methods of Selecting Subjects for Combination Cancer Therapy with a Polymer-conjugated Soluble PH20

20 Nov 19

Provided herein are methods of selecting subjects having cancer for combination therapy that includes administering an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme.

Song Wang, Darin M. Taverna, Carl Di Casoli, Nicholas Willumsen, Morten Karsdal, Thomas Mueller

Filed: 14 May 19

Utility

Modified Hyaluronidases and Uses In Treating Hyaluronan-associated Diseases and Conditions

6 Nov 19

Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders.

Gregory I. Frost, Ping Jiang, Curtis B. Thompson

Filed: 20 May 19